KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $13.3 million.

  • Adaptive Biotechnologies' Share-based Compensation fell 195.98% to $13.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.6 million, marking a year-over-year decrease of 841.23%. This contributed to the annual value of $53.6 million for FY2024, which is 1478.03% down from last year.
  • According to the latest figures from Q3 2025, Adaptive Biotechnologies' Share-based Compensation is $13.3 million, which was down 195.98% from $13.4 million recorded in Q2 2025.
  • Adaptive Biotechnologies' Share-based Compensation's 5-year high stood at $17.3 million during Q2 2023, with a 5-year trough of $8.5 million in Q1 2021.
  • For the 5-year period, Adaptive Biotechnologies' Share-based Compensation averaged around $13.4 million, with its median value being $13.4 million (2025).
  • Its Share-based Compensation has fluctuated over the past 5 years, first surged by 8051.06% in 2021, then tumbled by 2529.26% in 2024.
  • Quarter analysis of 5 years shows Adaptive Biotechnologies' Share-based Compensation stood at $11.9 million in 2021, then increased by 20.37% to $14.3 million in 2022, then rose by 8.83% to $15.6 million in 2023, then fell by 17.51% to $12.8 million in 2024, then rose by 3.31% to $13.3 million in 2025.
  • Its Share-based Compensation was $13.3 million in Q3 2025, compared to $13.4 million in Q2 2025 and $12.1 million in Q1 2025.